03.01.04
In early January, Nutrition 21, Purchase, NY, filed a health claim petition with FDA requesting that it allow use of eight dietary supplement health claims associating chromium picolinate supplementation with a reduced risk of insulin resistance, type 2 diabetes and related disease conditions. FDA has accepted the health claim petition as complete and has initiated the review process. The proposed health claims include:
• Chromium picolinate may reduce insulin resistance.
• Chromium picolinate may reduce the risk of cardiovascular disease when caused by insulin resistance.
• Chromium picolinate may reduce the risk of abnormally elevated blood sugar levels.
• Chromium picolinate may reduce the risk of cardiovascular disease when caused by abnormally high blood sugar levels.
• Chromium picolinate may reduce the risk of type 2 diabetes.
• Chromium picolinate may reduce the risk of cardiovascular disease when caused by type 2 diabetes.
• Chromium picolinate may reduce the risk of retinopathy when caused by abnormally high blood sugar levels.
• Chromium picolinate may reduce the risk of kidney disease when caused by abnormally high blood sugar levels.
• Chromium picolinate may reduce insulin resistance.
• Chromium picolinate may reduce the risk of cardiovascular disease when caused by insulin resistance.
• Chromium picolinate may reduce the risk of abnormally elevated blood sugar levels.
• Chromium picolinate may reduce the risk of cardiovascular disease when caused by abnormally high blood sugar levels.
• Chromium picolinate may reduce the risk of type 2 diabetes.
• Chromium picolinate may reduce the risk of cardiovascular disease when caused by type 2 diabetes.
• Chromium picolinate may reduce the risk of retinopathy when caused by abnormally high blood sugar levels.
• Chromium picolinate may reduce the risk of kidney disease when caused by abnormally high blood sugar levels.